Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases
Authors
Keywords
-
Journal
TOXICOLOGY IN VITRO
Volume 92, Issue -, Pages 105664
Publisher
Elsevier BV
Online
2023-08-18
DOI
10.1016/j.tiv.2023.105664
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
- (2022) Veerandra Kumar et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase
- (2021) Xiaoyu Wang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development
- (2021) Michael J. Hanley et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug‐drug interactions
- (2020) Zhe Wang et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Clinical Studies on Drug‐Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls and Interpretation
- (2019) Aleksi Tornio et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
- (2019) Robyn Meech et al. PHYSIOLOGICAL REVIEWS
- In vitro to in vivo extrapolation for high throughput prioritization and decision making
- (2018) Shannon M. Bell et al. TOXICOLOGY IN VITRO
- The Inhibition of UDP-Glucuronosyltransferase (UGT) Isoforms by Praeruptorin A and B
- (2016) Xin Liu et al. PHYTOTHERAPY RESEARCH
- Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications
- (2014) C Guillemette et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
- (2013) S. I. Shibata et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
- (2013) Narayana I. Narasimhan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study
- (2013) Justin Stebbing et al. PLoS One
- The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
- (2012) R. Sen et al. MOLECULAR CANCER THERAPEUTICS
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases
- (2009) Y. Liu et al. DRUG METABOLISM AND DISPOSITION
- Effect of D256N and Y483D on Propofol Glucuronidation by Human Uridine 5′-diphosphate Glucuronosyltransferase (UGT1A9)
- (2008) Hiroko Takahashi et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More